Long-term Registry of Patients Treated With Loncastuximab Tesirine

ADC Therapeutics

Status: Withdrawn

Conditions: B-Cell Lymphomas

Study type: Observational

Funder types: Industry

Identifiers

NCT05160064

ADCT-402-N01

Details and patient eligibility

About

Retrospective and prospective multi-center observational study of patients with B-cell lymphomas treated with loncastuximab tesirine treatment in real-world practice.

Full description

The purpose of this study is to assess treatment patterns and generate evidence on the effectiveness and safety of loncastuximab tesirine treatment in real-world practice. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must be ≥ 18 years of age at the time of consent.
• Initiated or initiating commercially available loncastuximab tesirine treatment.
• Written informed consent must be obtained prior to any registry activities.

Exclusion criteria

• Prior loncastuximab tesirine exposure in clinical trials.

Trial design

0 participants in 1 patient group

Patients Treated with Loncastuximab Tesirine

Description:

Patients with B-cell lymphomas and other diagnoses who have been treated with loncastuximab tesirine will have their medical chart data entered into the registry.